TG THERAPEUTICS, INC. (TGTX)
Data as of , from SEC Form 4 filings.
See up to 3 months of TGTX. The 7-day demo opens the 1M and 3M ranges and puts TGTX on your watchlist.
Start 7-day demoLatest TGTX insider trades
About TG THERAPEUTICS, INC. (TGTX)
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
- NEW YORK, NY
- 399
- 1995
- Nasdaq
TGTX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 5,000 | $275K |
| Bona-fide gift | 3 | 6,050 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
TGTX insider transactions (Form 4)
2519 Form 4 filings on record, the earliest from Nov 7, 2024, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Laurence N. Charney - Director | Open-market sale | Common Stock | 5,000 footnote F1 | $54.96 footnote F2 | $275K | |
| ||||||
| Laurence N. Charney - Director | Gift | Common Stock | 5,100 footnote F1 | $0.00 | - | |
| Laurence N. Charney - Director | Gift | Common Stock | 500 footnote F1 | $0.00 | - | |
| Laurence N. Charney - Director | Gift | Common Stock | 450 footnote F1 | $0.00 | - | |
| ||||||
| Sagar Lonial - Director | Grant or award | Stock Tracking Unit | 8,325 | $0.00 | - | |
| Daniel Hume - Director | Grant or award | Stock Tracking Unit | 8,325 | $0.00 | - | |
| Kenneth Hoberman - Director | Grant or award | Stock Tracking Unit | 8,325 | $0.00 | - | |
| Yann Echelard - Director | Grant or award | Stock Tracking Unit | 8,325 | $0.00 | - | |
| Laurence N. Charney - Director | Grant or award | Stock Tracking Unit | 8,325 | $0.00 | - | |
| Laurence N. Charney - Director | Gift | Common Stock | 30,000 footnote F1 | $0.00 | - | |
| Laurence N. Charney - Director | Gift | Common Stock | 13,197 footnote F1 | $0.00 | - | |
| ||||||
| Yann Echelard - Director | Open-market sale | Common Stock | 5,000 footnote F1 | $32.57 | $163K | |
| ||||||
| Michael S. Weiss - Officer | Gift | Common Stock | 3,865,126 footnote F1 | $0.00 | - | |
| Michael S. Weiss - Officer | Gift | Common Stock | 803,717 footnote F3 | $0.00 | - | |
| ||||||
| Sagar Lonial - Director | Open-market sale | Common Stock | 20,852 | $32.24 | $672K | |
| Yann Echelard - Director | Grant or award | Common Stock | 14,718 | $0.00 | - | |
| Yann Echelard - Director | Open-market sale | Common Stock | 10,000 | $36.94 | $369K | |
| Laurence N. Charney - Director | Grant or award | Common Stock | 21,408 | $0.00 | - | |
| Kenneth Hoberman - Director | Grant or award | Common Stock | 14,718 | $0.00 | - | |
| Daniel Hume - Director | Grant or award | Common Stock | 14,718 | $0.00 | - | |
| Sagar Lonial - Director | Grant or award | Common Stock | 14,718 | $0.00 | - | |
| Sagar Lonial - Director | Open-market sale | Common Stock | 5,000 | $30.44 | $152K | |
| Laurence N. Charney - Director | Open-market sale | Common Stock | 25,000 | $30.20 | $755K | |
| Laurence N. Charney - Director | Gift | Common Stock | 5,000 | $0.00 | - | |
| Yann Echelard - Director | Open-market sale | Common Stock | 20,000 | $24.48 | $490K | |
Recent TGTX Form 144 notices of proposed sale
1An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Laurence N. Charney | Director | 5,000 | $275K | View on EDGAR |
TGTX insider trading FAQ
What is the latest insider trade for TGTX?
TG THERAPEUTICS, INC. (TGTX) had 2 insider filings in the last 90 days, with the most recent on 14 September 2026. The full record for TGTX runs to 19 Form 4 filings, the earliest from 7 November 2024. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying TGTX stock?
No insider purchases of TGTX were filed in the last 90 days.
How many insiders are selling TGTX stock?
1 insider sale of TGTX was filed in the last 90 days, totaling $275K.
Where can I see TGTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects TGTX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Laurence N. Charney view on EDGAR
- - Laurence N. Charney view on EDGAR
- - Sagar Lonial view on EDGAR
- - Daniel Hume view on EDGAR
- - Kenneth Hoberman view on EDGAR
- - Yann Echelard view on EDGAR
- - Laurence N. Charney view on EDGAR
- - Laurence N. Charney view on EDGAR
- - Yann Echelard view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where TGTX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow TGTX with a 7-day demo
- TGTX on your watchlist
- Every TGTX Form 4 filing on record
- Up to 3 months of TGTX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
